Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/18/17
End: 01/10/20
Due: 01/10/21
Phase: N/A
Priority: Normal
Start: 10/11/16
End: 11/07/18
Due: 11/07/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma | NCT02809053 | Archigen Biotech Limited | user2@example.com | None | 2017-01-18 | 2020-01-10 | 2021-01-10 | - | - | 2025-07-14 |
| PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis | NCT02819726 | Archigen Biotech Limited | user2@example.com | None | 2016-10-11 | 2018-11-07 | 2019-11-07 | - | - | 2025-07-14 |